PDCD1 and neoplasm: Therefore, immunotherapies target co-inhibitory receptors, such as CTLA-4, PD-1, and PD-L1, on tumor cells or immune cells, in order to prevent T cell dysfunction and apoptosis and enhance T cells’ ability to kill tumor cells [25].